PureTech Health plc

Declaration of Voting Results & Voting Rights Announcements • Mar 3, 2025

National Storage Mechanism | Additional information

RNS Number : 9471Y

PureTech Health PLC

03 March 2025

PureTech Health plc

Total Voting Rights and Share Capital - Month End Disclosure

Pursuant to DTR 5.6.1 of the Disclosure Guidance and Transparency Rules:

As at 28 February 2025 the issued share capital of PureTech Health plc comprised 257,927,489 Ordinary Shares of one pence each. There were 17,738,040 shares held in treasury.

The total number of voting rights in PureTech Health plc is therefore 240,189,449.

This information may be used by shareholders in their calculations to determine if they are required to notify their interest in, or a change to their interest in, PureTech Health plc under the FCA's Disclosure Guidance and Transparency Rules. 

About PureTech Health

PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad and deep pipeline through its experienced research and development team and its extensive network of scientists, clinicians and industry leaders that is being advanced both internally and through its Founded Entities. PureTech's R&D engine has resulted in the development of 29 therapeutics and therapeutic candidates, including three that have been approved by the U.S. Food and Drug Administration. A number of these programs are being advanced by PureTech or its Founded Entities in various indications and stages of clinical development, including registration enabling studies. All of the underlying programs and platforms that resulted in this pipeline of therapeutic candidates were initially identified or discovered and then advanced by the PureTech team through key validation points.

For more information, visit  www.puretechhealth.com  or connect with us on X (formerly Twitter) @puretechh.

Contact: Investor Relations IR@puretechhealth.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

TVRPPUCCPUPAGAR